DE2837168A1
(de)
|
1978-08-25 |
1980-03-06 |
Blutspendedienst Dt Rote Kreuz |
Verfahren zur herstellung einer fuer die intravenoese anwendung geeigneten immunglobulinloesung
|
US4362661A
(en)
|
1979-08-09 |
1982-12-07 |
Teijin Limited |
Immunoglobulin composition having a high monomer content, and process for production thereof
|
US4360457A
(en)
|
1979-08-30 |
1982-11-23 |
Teijin Limited |
S-Sulfonated immunoglobulin composition having a high monomer content and a process for production thereof
|
US4374763A
(en)
|
1979-09-17 |
1983-02-22 |
Morishita Pharmaceutical Co., Ltd. |
Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
|
US4396608A
(en)
|
1981-08-24 |
1983-08-02 |
Cutter Laboratories |
Intravenously injectable immune serum globulin
|
US5702699A
(en)
|
1982-09-23 |
1997-12-30 |
Cetus Corporation |
Process for the recovery of lipophilic proteins
|
US4681713A
(en)
|
1984-03-15 |
1987-07-21 |
Toyo Boseki Kabushiki Kaisha |
Method of making a hollow fiber membrane for dialysis
|
US4597966A
(en)
|
1985-01-09 |
1986-07-01 |
Ortho Diagnostic Systems, Inc. |
Histidine stabilized immunoglobulin and method of preparation
|
US6673347B1
(en)
|
1986-04-30 |
2004-01-06 |
Gryphon Therapeutics |
Polypeptide and protein derivatives and process for their preparation
|
GB8628104D0
(en)
|
1986-11-25 |
1986-12-31 |
Connaught Lab |
Pasteurization of immunoglobin solutions
|
DE3640513A1
(de)
|
1986-11-27 |
1988-06-09 |
Biotest Pharma Gmbh |
Verfahren zur herstellung eines virussicheren, lagerstabilen und intravenoes vertraeglichen immunglobulin-g-praeparates
|
JP2547556B2
(ja)
|
1987-02-06 |
1996-10-23 |
株式会社 ミドリ十字 |
r−グロブリンの液状製剤
|
WO1990005183A1
(en)
|
1988-10-31 |
1990-05-17 |
Immunex Corporation |
Interleukin-4 receptors
|
US5395760A
(en)
|
1989-09-05 |
1995-03-07 |
Immunex Corporation |
DNA encoding tumor necrosis factor-α and -β receptors
|
EP1132471A3
(de)
|
1989-09-12 |
2001-11-28 |
F. Hoffmann-La Roche Ag |
TNF-bindende Proteine
|
DE3939346A1
(de)
|
1989-11-29 |
1991-06-06 |
Behringwerke Ag |
Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
|
US5177194A
(en)
|
1990-02-01 |
1993-01-05 |
Baxter International, Inc. |
Process for purifying immune serum globulins
|
US5945098A
(en)
|
1990-02-01 |
1999-08-31 |
Baxter International Inc. |
Stable intravenously-administrable immune globulin preparation
|
GB9017002D0
(en)
|
1990-08-02 |
1990-09-19 |
Health Lab Service Board |
Improved method for the purification of erwina l-asparaginase
|
JP3179538B2
(ja)
|
1990-12-11 |
2001-06-25 |
ノバルティス アクチエンゲゼルシャフト |
安定なヒトカルシトニンの水性溶液
|
US5110910A
(en)
|
1991-03-25 |
1992-05-05 |
Miles Inc. |
Virucidal euglobulin precipitation
|
US5256571A
(en)
|
1991-05-01 |
1993-10-26 |
Cytyc Corporation |
Cell preservative solution
|
WO1993013133A1
(en)
|
1991-12-20 |
1993-07-08 |
Yamanouchi Pharmaceutical Co., Ltd. |
HUMAN TYPE ANTIBODY REACTIVE WITH GPIIb/IIIa
|
US6004555A
(en)
|
1992-03-05 |
1999-12-21 |
Board Of Regents, The University Of Texas System |
Methods for the specific coagulation of vasculature
|
US5298410A
(en)
|
1993-02-25 |
1994-03-29 |
Sterling Winthrop Inc. |
Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
|
US5484892A
(en)
|
1993-05-21 |
1996-01-16 |
Dana-Farber Cancer Institute, Inc. |
Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
|
DE4344824C1
(de)
|
1993-12-28 |
1995-08-31 |
Immuno Ag |
Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
|
GB9401448D0
(en)
|
1994-01-26 |
1994-03-23 |
Ciba Geigy Ag |
Stable dry powders
|
US5580856A
(en)
|
1994-07-15 |
1996-12-03 |
Prestrelski; Steven J. |
Formulation of a reconstituted protein, and method and kit for the production thereof
|
IL114909A
(en)
|
1994-08-12 |
1999-10-28 |
Immunomedics Inc |
Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
CN101712720A
(zh)
|
1996-02-09 |
2010-05-26 |
艾博特生物技术有限公司 |
结合人TNFα的人抗体
|
TW518219B
(en)
|
1996-04-26 |
2003-01-21 |
Chugai Pharmaceutical Co Ltd |
Erythropoietin solution preparation
|
GB9610992D0
(en)
|
1996-05-24 |
1996-07-31 |
Glaxo Group Ltd |
Concentrated antibody preparation
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
CA2261291A1
(en)
|
1996-07-18 |
1998-01-29 |
Csl Limited |
Pasteurization of immunoglobulin solutions
|
TW491855B
(en)
|
1996-08-07 |
2002-06-21 |
Csl Ltd |
Purification of immunoglobulins
|
EP0852951A1
(de)
|
1996-11-19 |
1998-07-15 |
Roche Diagnostics GmbH |
Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
US5886154A
(en)
|
1997-06-20 |
1999-03-23 |
Lebing; Wytold R. |
Chromatographic method for high yield purification and viral inactivation of antibodies
|
JP3679406B2
(ja)
|
1998-05-20 |
2005-08-03 |
協和醗酵工業株式会社 |
遺伝子組換え抗体
|
US6436897B2
(en)
|
1998-06-01 |
2002-08-20 |
Celtrix Pharmaceuticals, Inc. |
Pharmaceutical formulations for IGF/IGFBP
|
JP4685238B2
(ja)
|
1998-06-09 |
2011-05-18 |
ツエー・エス・エル・ベーリング・アクチエンゲゼルシヤフト |
静脈投与用免疫グロブリン及び他の免疫グロブリン生成物の製造法
|
US6610206B1
(en)
|
1998-10-20 |
2003-08-26 |
Advanced Renal Technologies |
Buffered compositions for dialysis
|
IL127127A0
(en)
|
1998-11-18 |
1999-09-22 |
Peptor Ltd |
Small functional units of antibody heavy chain variable regions
|
US7294481B1
(en)
|
1999-01-05 |
2007-11-13 |
Immunex Corporation |
Method for producing recombinant proteins
|
EP2332976B1
(en)
|
1999-02-03 |
2014-04-02 |
Amgen, Inc |
Novel polypeptides involved in immune response
|
DK1165119T3
(da)
|
1999-04-08 |
2003-12-15 |
Genentech Inc |
Sammensætning baseret på modsat ladede polypeptider
|
DK1181036T3
(da)
|
1999-04-09 |
2008-11-24 |
Ortho Mcneil Pharm Inc |
Farmaceutiske sammensætninger af erythropoietin
|
US20040220103A1
(en)
|
1999-04-19 |
2004-11-04 |
Immunex Corporation |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
US20010021380A1
(en)
|
1999-04-19 |
2001-09-13 |
Pluenneke John D. |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
CA2366785C
(en)
|
1999-04-19 |
2012-02-07 |
Immunex Corporation |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
EP1220682B1
(en)
|
1999-10-04 |
2006-11-22 |
Novartis Vaccines and Diagnostics, Inc. |
Stabilized liquid polypeptide-containing pharmaceutical compositions
|
NZ519222A
(en)
|
1999-12-14 |
2004-04-30 |
Genentech Inc |
TNF-alpha antagonists and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder
|
AU2262501A
(en)
|
1999-12-16 |
2001-06-25 |
Amgen, Inc. |
Tnfr/opg-like molecules and uses thereof
|
JP2003522155A
(ja)
|
2000-02-10 |
2003-07-22 |
ワイス |
細胞損傷または細胞死を治療または阻害する方法
|
ES2267593T3
(es)
|
2000-02-16 |
2007-03-16 |
Genentech, Inc. |
Anticuerpos anti-april y celulas hibridomas.
|
US20050209447A1
(en)
|
2000-07-25 |
2005-09-22 |
Takashi Ito |
Process for producing recombinant protein
|
JP5490972B2
(ja)
|
2000-08-04 |
2014-05-14 |
中外製薬株式会社 |
タンパク質注射製剤
|
WO2002013860A1
(fr)
|
2000-08-11 |
2002-02-21 |
Chugai Seiyaku Kabushiki Kaisha |
Preparations stabilisees contenant un anticorps
|
AU2002213441B2
(en)
|
2000-10-12 |
2006-10-26 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
MXPA03005327A
(es)
|
2000-12-14 |
2004-12-03 |
Fujisawa Pharmaceutical Co |
Anticuerpos anti-cd28 silenciados y el uso de estos.
|
US6693173B2
(en)
|
2000-12-26 |
2004-02-17 |
Alpha Therapeutic Corporation |
Method to remove citrate and aluminum from proteins
|
WO2002053596A2
(en)
|
2001-01-05 |
2002-07-11 |
Pfizer Inc. |
Antibodies to insulin-like growth factor i receptor
|
ES2184594B1
(es)
|
2001-01-17 |
2004-01-01 |
Probitas Pharma Sa |
Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
|
CZ20032208A3
(cs)
|
2001-02-23 |
2004-01-14 |
Immunex Corporation |
Zvýšený výtěžek aktivních proteinů
|
GB0113179D0
(en)
|
2001-05-31 |
2001-07-25 |
Novartis Ag |
Organic compounds
|
JP2004521474A
(ja)
|
2001-06-25 |
2004-07-15 |
コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ |
高圧ガス放電ランプおよび高圧ガス放電ランプの製造方法
|
CN1547486A
(zh)
|
2001-06-26 |
2004-11-17 |
|
抗opgl抗体
|
WO2004081026A2
(en)
|
2003-06-30 |
2004-09-23 |
Domantis Limited |
Polypeptides
|
US7153507B2
(en)
*
|
2001-08-23 |
2006-12-26 |
Genmab A/S |
Human antibodies specific for interleukin 15 (IL-15)
|
US7247304B2
(en)
|
2001-08-23 |
2007-07-24 |
Genmab A/S |
Methods of treating using anti-IL-15 antibodies
|
WO2003024388A2
(en)
|
2001-09-20 |
2003-03-27 |
Cornell Research Foundation, Inc. |
Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
|
EP1441589B1
(en)
|
2001-11-08 |
2012-05-09 |
Abbott Biotherapeutics Corp. |
Stable liquid pharmaceutical formulation of igg antibodies
|
AU2002359495A1
(en)
|
2001-11-30 |
2003-06-17 |
Centocor, Inc. |
Anti-tnf antibodies, compositions, methods and uses
|
US7122641B2
(en)
|
2001-12-21 |
2006-10-17 |
Immunex Corporation |
Methods for purifying protein
|
JP4364645B2
(ja)
|
2002-02-14 |
2009-11-18 |
中外製薬株式会社 |
抗体含有溶液製剤
|
EP1476120B1
(en)
|
2002-02-21 |
2010-09-29 |
Duke University |
Treatment methods using anti-cd22 antibodies
|
SI1478394T1
(sl)
|
2002-02-27 |
2008-12-31 |
Immunex Corp |
STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
|
MXPA04009381A
(es)
|
2002-03-27 |
2005-01-25 |
Immunex Corp |
Metodos para incrementar la produccion de polipeptidos.
|
EP1494714A4
(en)
|
2002-04-05 |
2008-03-05 |
Amgen Inc |
HUMAN ANTI-OPGL NEUTRALIZING ANTIBODIES AS SELECTIVE OPGL PATH HEMMER
|
DK1501369T3
(en)
|
2002-04-26 |
2015-09-28 |
Genentech Inc |
Non-affinity purification of proteins
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
GB0210121D0
(en)
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
CA2490423A1
(en)
|
2002-06-21 |
2003-12-31 |
Biogen Idec Inc. |
Buffered formulations for concentrating antibodies and methods of use thereof
|
KR20050042466A
(ko)
|
2002-07-19 |
2005-05-09 |
애보트 바이오테크놀로지 리미티드 |
TNFα 관련 질환의 치료
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
US7674885B2
(en)
|
2002-11-01 |
2010-03-09 |
Bayer Healthcare Llc |
Process for concentration of macromolecules
|
US20040086532A1
(en)
|
2002-11-05 |
2004-05-06 |
Allergan, Inc., |
Botulinum toxin formulations for oral administration
|
NZ541253A
(en)
|
2002-12-20 |
2010-03-26 |
Amgen Inc |
Peptide binding agents which inhibit myostatin
|
EP1603948A1
(en)
|
2003-03-14 |
2005-12-14 |
Pharmacia Corporation |
Antibodies to igf-i receptor for the treatment of cancers
|
ZA200507757B
(en)
|
2003-04-04 |
2007-01-31 |
Genentech Inc |
High concentration antibody and protein formulations
|
JP4850709B2
(ja)
|
2003-05-14 |
2012-01-11 |
ダニスコ・ユーエス・インコーポレーテッド |
反復配列タンパク質ポリマーを使用する、活性剤の制御放出
|
US7354578B2
(en)
|
2003-06-06 |
2008-04-08 |
Regeneron Pharmaceuticals, Inc. |
Method of tumor regression with VEGF inhibitors
|
ATE548388T1
(de)
|
2003-11-07 |
2012-03-15 |
Immunex Corp |
An den interleukin-4-rezeptor bindende antikörper
|
EP1532983A1
(en)
|
2003-11-18 |
2005-05-25 |
ZLB Bioplasma AG |
Immunoglobulin preparations having increased stability
|
CN1953768B
(zh)
|
2004-02-12 |
2010-10-13 |
默克专利有限公司 |
抗-egfr抗体的高浓缩液体制剂
|
US20070292346A1
(en)
|
2004-03-25 |
2007-12-20 |
Rong Fan |
Lng105 Antibody Composition and Methods of Use, and Use of Lng105 to Assess Lung Cancer Risk
|
CN103393601A
(zh)
|
2004-05-12 |
2013-11-20 |
巴克斯特国际公司 |
含有蛋白并在高浓度蛋白下显示可注射性的微球体
|
WO2006003999A1
(ja)
|
2004-07-05 |
2006-01-12 |
Juridical Foundation The Chemo-Sero-Therapeutic Research Institute |
ヒト抗ヒトb7rp-1抗体およびその抗体フラグメント
|
US7648742B2
(en)
*
|
2004-07-29 |
2010-01-19 |
Merck Patent Gmbh |
Difluorosubstituted heterocyclic compounds and the use thereof in the form of components in liquid crystalline media
|
TW200621282A
(en)
|
2004-08-13 |
2006-07-01 |
Wyeth Corp |
Stabilizing formulations
|
US7300773B2
(en)
|
2004-08-27 |
2007-11-27 |
Wyeth Research Ireland Limited |
Production of TNFR-Ig
|
CA2581208A1
(en)
|
2004-08-30 |
2006-03-09 |
Lonza Biologics Plc. |
Affinity- plus ion exchange- chromatography for purifying antibodies
|
US20060051347A1
(en)
|
2004-09-09 |
2006-03-09 |
Winter Charles M |
Process for concentration of antibodies and therapeutic products thereof
|
WO2006064373A2
(en)
|
2004-12-16 |
2006-06-22 |
Genzyme Polyclonals S.A.S. |
Methods of purifying immunologlobulins
|
JP4498939B2
(ja)
|
2005-02-01 |
2010-07-07 |
東京応化工業株式会社 |
ポジ型レジスト組成物およびレジストパターン形成方法
|
US8597709B2
(en)
|
2005-04-12 |
2013-12-03 |
Inovobiologic Inc. |
Dietary supplement and methods of use
|
EA012801B1
(ru)
|
2005-06-14 |
2009-12-30 |
Эмджен Инк. |
Самобуферирующиеся композиции белков
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US20070049732A1
(en)
|
2005-09-01 |
2007-03-01 |
Zurlo Eugene J |
Ultra-high yield intravenous immune globulin preparation
|
US8877281B2
(en)
|
2005-09-21 |
2014-11-04 |
Burcon Nutrascience (Mb) Corp. |
Preparation of canola protein isolate involving isoelectric precipitation
|
US8067350B2
(en)
|
2005-12-15 |
2011-11-29 |
Kimberly-Clark Worldwide, Inc. |
Color changing cleansing composition
|
US20070202051A1
(en)
|
2006-02-10 |
2007-08-30 |
Pari Gmbh |
Aerosols for sinunasal drug delivery
|
CA2649538C
(en)
|
2006-04-21 |
2014-06-03 |
Yatin Gokarn |
Buffering agents for biopharmaceutical formulations
|
JP5290152B2
(ja)
|
2006-04-21 |
2013-09-18 |
ノバルティス アーゲー |
拮抗剤抗cd40抗体薬学的組成物
|
EP2059523A2
(en)
|
2006-09-15 |
2009-05-20 |
Barofold, Inc. |
High pressure treatment of proteins for reduced immunogenicity
|
CA2667655A1
(en)
|
2006-10-27 |
2008-05-15 |
Abbott Biotechnology Ltd. |
Crystalline anti-htnfalpha antibodies
|
CA2790018C
(en)
|
2006-12-21 |
2015-02-03 |
Amgen Inc. |
Formulations
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
CA2904458C
(en)
|
2007-11-30 |
2017-07-25 |
Wolfgang Fraunhofer |
Protein formulations and methods of making same
|
US20110060290A1
(en)
*
|
2008-02-07 |
2011-03-10 |
Amgen Inc. |
Stabilized protein compositions
|
EP2276527B1
(en)
|
2008-05-20 |
2018-02-28 |
Avant Medical Corp. |
Autoinjector system
|
US8177749B2
(en)
|
2008-05-20 |
2012-05-15 |
Avant Medical Corp. |
Cassette for a hidden injection needle
|
US8052645B2
(en)
|
2008-07-23 |
2011-11-08 |
Avant Medical Corp. |
System and method for an injection using a syringe needle
|
CN102159204B
(zh)
*
|
2008-09-19 |
2015-04-01 |
辉瑞公司 |
稳定的液体抗体制剂
|
MX345226B
(es)
*
|
2008-10-29 |
2017-01-20 |
Ablynx Nv |
Formulaciones de moleculas de union a antigeno de dominio sencillo.
|
RU2011140498A
(ru)
|
2009-03-06 |
2013-04-20 |
Дженентек, Инк. |
Препарат антител
|
US20110070227A1
(en)
|
2009-09-18 |
2011-03-24 |
Anna-Marie Novotney-Barry |
Treatment of Autoimmune and Inflammatory Diseases
|
MX344727B
(es)
|
2010-11-11 |
2017-01-05 |
Abbvie Biotechnology Ltd |
Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
|
US9173999B2
(en)
*
|
2011-01-26 |
2015-11-03 |
Kaleo, Inc. |
Devices and methods for delivering medicaments from a multi-chamber container
|
CA2833427C
(en)
*
|
2011-04-20 |
2019-09-24 |
Sandoz Ag |
Stable pharmaceutical liquid formulations of the fusion protein tnfr:fc
|
LT2699293T
(lt)
|
2011-04-20 |
2019-04-25 |
Amgen Inc. |
Automatinio purškimo prietaisas
|
UY34105A
(es)
*
|
2011-06-03 |
2012-07-31 |
Lg Life Sciences Ltd |
Formulación líquida estable de etanercept
|
KR102061355B1
(ko)
|
2011-07-01 |
2019-12-31 |
바이오젠 엠에이 인코포레이티드 |
아르기닌-없는 tnfr : fc-융합 폴리펩티드 조성물 및 이용 방법
|
JP6113176B2
(ja)
*
|
2011-10-18 |
2017-04-12 |
コヒラス・バイオサイエンシズ・インコーポレイテッド |
キシリトールによって安定化されたエタネルセプト製剤
|
WO2013186230A1
(en)
*
|
2012-06-12 |
2013-12-19 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical formulation for a therapeutic antibody
|
EP2869871B1
(en)
|
2012-07-05 |
2021-03-17 |
UNL Holdings LLC |
Automatic injectors for injectable cartridges and drive control mechanisms therefor
|
EA029193B1
(ru)
*
|
2012-07-09 |
2018-02-28 |
Кохерус Байосайенсис, Инк. |
Составы этанерцепта, отличающиеся заметным уменьшением содержания частиц довидимого диапазона
|
IN2015KN00452A
(ja)
*
|
2012-09-11 |
2015-07-17 |
Coherus Biosciences Inc |
|
US10058589B2
(en)
|
2012-10-26 |
2018-08-28 |
Lupin Limited |
Stable pharmaceutical composition of Etanercept in a phosphate citrate buffer with glycine as an anti-aggregating agent
|
EP2919812A4
(en)
|
2012-11-19 |
2016-05-18 |
Merck Sharp & Dohme |
Liquid formulations for TNFR: FC fusion proteins
|
WO2014084508A1
(ko)
*
|
2012-11-27 |
2014-06-05 |
(주)알테오젠 |
단백질과 Fc 도메인을 융합한 융합 단백질의 안정화용 조성물
|
US9452138B2
(en)
|
2012-12-28 |
2016-09-27 |
Abbott Cardiovascular Systems Inc. |
Delivery of biologic therapeutics
|
TWI639449B
(zh)
|
2013-03-15 |
2018-11-01 |
美商安美基公司 |
用於注射器之匣盒
|
CA2904725C
(en)
|
2013-03-15 |
2022-04-12 |
Amgen Inc. |
Drug cassette, autoinjector, and autoinjector system
|
JP2016518386A
(ja)
*
|
2013-05-02 |
2016-06-23 |
マブキシェンス エス.アー. |
TNFR:Fc融合ポリペプチドの代替配合物
|
KR20210041101A
(ko)
*
|
2013-10-24 |
2021-04-14 |
아스트라제네카 아베 |
안정한 수성 항체 제제
|
KR101712245B1
(ko)
*
|
2013-11-29 |
2017-03-06 |
아레스 트레이딩 에스.에이. |
TNFR 및 면역글로블린 Fc 영역을 포함하는 융합 단백질을 포함하는 액상 제제
|
ES2733298T3
(es)
|
2014-07-18 |
2019-11-28 |
Sandoz Ag |
Cuantificación de TNFR2:Fc plegado erróneamente
|
EP3733228B1
(en)
|
2014-08-28 |
2024-03-06 |
UNL Holdings LLC |
Sensor systems for drug delivery devices
|
CN107106769A
(zh)
|
2014-08-28 |
2017-08-29 |
尤尼特拉克特注射器控股有限公司 |
用于药物递送装置的皮肤传感器
|
ES2833506T3
(es)
|
2014-12-22 |
2021-06-15 |
Ares Trading Sa |
Composición farmacéutica líquida
|
EP3268042A4
(en)
|
2015-03-13 |
2018-08-01 |
Samsung Bioepis Co., Ltd. |
Anti-tnf-alpha polypeptide composition and use thereof
|
US9763976B1
(en)
|
2016-08-02 |
2017-09-19 |
Zo Skin Health, Inc. |
Composition and method for treating skin conditions
|
EP3528787A4
(en)
|
2016-10-21 |
2020-05-06 |
Amgen Inc. |
PHARMACEUTICAL FORMULATIONS AND PROCESSES FOR THEIR PREPARATION
|